(Q28480940)

7

0 references

Frauke Zipp

6

0 references

Carmen Infante-Duarte

8

object named as

Carmen Infante-Duarte

0 references

Jason M Millward

object named as

Jason M Millward

2

0 references

author name string

Coralie Chanvillard

1

0 references

Marta Lozano

3

0 references

Isabell Hamann

Creative Commons Attribution 4.0 International

4

0 references

language of work or name

English

0 references

publication date

2012

0 references

published in

PLOS One

0 references

volume

7

0 references

issue

6

0 references

page(s)

e39625

0 references

copyright license

start time

29 June 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Serial Assessment of Cardiac Function during and following Mitoxantrone Infusion in 30 Consecutive Patients with Multiple Sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

The phagocytes: neutrophils and monocytes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

New developments in understanding and treating neuroinflammation.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

Neuronal damage in brain inflammation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

Mechanism of action of mitoxantrone

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

Profiling the CD8low phenotype, an alternative career choice for CD8 T cells during primary differentiation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

Molecular and biochemical pharmacology of mitoxantrone

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

Mitoxantrone and cytotoxic drugs' mechanisms of action

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

2 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

CD27 defines phenotypically and functionally different human NK cell subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039625

Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387260

Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function

27 November 2018

1 reference

12 December 2020

Neutrophils in multiple sclerosis are characterized by a primed phenotype

1 reference

12 December 2020

Human CD8 T cells of the peripheral blood contain a low CD8 expressing cytotoxic/effector subpopulation

1 reference

12 December 2020

Natural killer cell activity in multiple sclerosis patients treated with recombinant interferon-alpha 2

1 reference

12 December 2020

Inhibition of the induction of alloreactivity with mitoxantrone

1 reference

12 December 2020

Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor

1 reference

12 December 2020

Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls

1 reference

12 December 2020

Extensive infiltration of neutrophils in the acute phase of experimental autoimmune encephalomyelitis in C57BL/6 mice

1 reference

12 December 2020

Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B

1 reference

12 December 2020

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study

1 reference

12 December 2020

Natural killer cell number and activity in multiple sclerosis

1 reference

12 December 2020